Trials of neuroprotective therapies for Parkinson’s disease: Problems and limitations
Authors:
- Raúl de la Fuente-FernándezRFRaúl de la Fuente-Fernández
- Michael SchulzerMSMichael Schulzer
- Edwin MakEMEdwin Mak
- Vesna SossiVSVesna Sossi
- 1 July 2010
- journal article
- review article
- Published by Elsevier in Parkinsonism & Related Disorders
- Vol. 16 (6) , 365-369
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Evidence that incidental Lewy body disease is pre-symptomatic Parkinson’s diseaseActa Neuropathologica, 2008
- Association of olfactory dysfunction with incidental Lewy bodiesMovement Disorders, 2006
- Epidemiology of Parkinson's diseaseThe Lancet Neurology, 2006
- A “cure” for Parkinson's disease: Can neuroprotection be proven with current trial designs?Movement Disorders, 2004
- Slowing Parkinson’s disease progressionNeurology, 2003
- Impact of sustained deprenyl (selegiline) in levodopa‐treated Parkinson's disease: A randomized placebo‐controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trialAnnals of Neurology, 2002
- Dopamine Transporter Brain Imaging to Assess the Effects of Pramipexole vs Levodopa on Parkinson Disease ProgressionJAMA, 2002
- Effects of Tocopherol and Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1993
- The antiparkinson efficacy of deprenyl derives from transient improvement that is likely to be symptomaticAnnals of Neurology, 1992
- Effect of Deprenyl on the Progression of Disability in Early Parkinson's DiseaseNew England Journal of Medicine, 1989